New drug target valid for breast cancer as well as lymphoma
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research.
The results provide more justification and rationale for starting the clinical trial in May. It s another exciting stepping stone to finding out if this is going to be a new cancer treatment.
John Mackey, First Author, Professor and Director of Oncology Clinical Trials, Faculty of Medicine & Dentistry, University of Alberta
The drug PCLX-001 is designed to selectively kill cancer cells by targeting enzymes involved in myristoylation, a process key to the cell signaling system that is often defective in cancer cells. The molecule was originally developed by the University of Dundee as a treatment for African sleeping sickness. U of A cell biologist Luc Berthiaume was the first to realize it could work aga
E-Mail
IMAGE: University of Alberta oncology researcher John Mackey (left) and cell biologist Luc Berthiaume are collaborators on new research showing that PCLX-001, an anti-cancer drug set to begin clinical trials this. view more
Credit: University of Alberta
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research. The results provide more justification and rationale for starting the clinical trial in May, said first author John Mackey, professor and director of oncology clinical trials in the Faculty of Medicine & Dentistry. It s another exciting stepping stone to finding out if this is going to be a new cancer treatment.